Skip to content

Investigation of the Characteristics of Chronic Pain Developing After COVID-19

Investigation of the Characteristics of Chronic Pain Developing After COVID-19 in Patients With COVID-19

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04883216
Enrollment
776
Registered
2021-05-12
Start date
2021-03-24
Completion date
2021-12-31
Last updated
2022-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Pain, Coronavirus, Covid19

Keywords

Chronic Pain, COVID19, Characteristics

Brief summary

Data on pain after COVID-19 were generally collected from hospitalized patients and only include information on acute pain conditions. However, the characteristics of the chronic pain experienced after COVID-19 are unknown. For this reason, the treatment and recommendations for patients who present with chronic pain after COVID-19 are not clear. Our goal is to determine the characteristics and risk factors of chronic pain developing in COVID-19 patients and to create specific treatment recommendations for these patient groups with further studies.

Detailed description

Data on pain developing after COVID-19 were generally collected from hospitalized patients and only include information on acute pain conditions seen after the ilness. It is noteworthy that headache and musculoskeletal pain were seen common in first few weeks. However, the characteristics (mechanical, inflammatory, central sensitization, anxiety-related, etc.) of the chronic pain experienced are unknown. For this reason, the treatment and recommendations for patients who present with chronic pain after COVID-19 are not clear. Our goal is to determine the characteristics and risk factors of chronic pain developing in COVID-19 patients and to create specific treatment recommendations for these patient groups with further studies.

Interventions

None listed

Sponsors

Istanbul University
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Being over the age of 18 2. SARS-CoV-2 infection demonstrated with the PCR test (testing date irrelevant) 3. Pain developed or increased after having COVID-19

Exclusion criteria

1\. Mental retardation or mental status not eligible to answer the questionnaires

Design outcomes

Primary

MeasureTime frameDescription
Self-Leeds Assessment of Neuropathic Symptoms & Signs (S-LANSS) Pain Scoreup to 1 yearThe S-LANSS aims to identify pain of predominantly neuropathic origin, as distinct from nociceptive pain, without the need for clinical examination.
The Hospital Anxiety and Depression Scale (HADS) Scoreup to 1 yearThe Hospital Anxiety and Depression Scale (HADS) is a self-assessment questionnaire that has been found to be a reliable instrument for detecting states of anxiety and depression in the setting of hospital outpatient clinic. The HADS questionnaire has seven items each for depression and anxiety subscales.
Central Sensitization Inventory (CSI)up to 1 yearThe Central Sensitisation Inventory (CSI) is a self-report outcome measure designed to identify patients who have symptoms that may be related to central sensitisation (CS) or central sensitivity syndromes (CSS) such as fibromyalgia, neck injury, temporomandibular joint disorder or migraine/tension headaches. CSI includes 25 questions related to common CSS symptoms.
Self-report Demographic Questionnaireup to 1 yearA questionnaire made by the researchers to understand the demographic characteristics of the patients included.
Visual Analog Scale (VAS) for Painup to 1 yearThe visual analog scale (VAS) is a validated, subjective measure for acute and chronic pain. Scores are recorded by making a handwritten mark on a 10-cm line that represents a continuum between no pain and worst pain.

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026